The most comprehensive study yet on child diarrhoea in developing countries takes aim at targeting more pathogens and providing better care.

Through a new US$100 million research fund, Japan will help finance the search for drugs to target the world's deadliest diseases.

A cheap vaccine developed in India against rotavirus could add substantially to protection against diarrhoea.

GM-produced artemisinin is deemed to be comparable in quality to the plant-derived version, but should be cheaper to produce.

A candidate vaccine against Chagas disease elicited high immunity in mice, and proved to be safe and simple to produce.

After a lengthy court battle, India has rejected a major cancer drug patent bid — meaning lifesaving drugs will remain cheap and accessible.

The majority of the clinical trials conducted in Latin America and the Caribbean are not focused on health areas of relevance to the region.

Chagas disease costs countries US$7 billion a year, with Latin America paying the greatest price, a study has found.

A rise in antibiotic-resistant infections is a huge problem for developing countries that often lack the money to tackle them, a conference hears.

The first new tuberculosis vaccine in almost a century did not increase protection against TB compared with existing vaccine, shows trial.

The Leishmania parasite uses a sugary secretion to outwit the human immune system and resist antimony drugs, say researchers.

Saudi researchers say they have discovered a cancer-curing compound in camel urine, but further trials are needed to test the claims.

Extracts from plants are used widely to treat malaria in Benin, and their conservation should be promoted, says a study.

Developed and developing nations must pool funding and expertise to deliver new drugs against neglected tropical diseases, urge health organisations.

Ecuador has authorised the development of a generic drug against HIV/AIDS, which will cost 75 per cent less than the patented version.

Strains of rotavirus earlier found only in animals are now infecting human beings.

The government of Zimbabwe has earmarked substantial funding to kick-start a nanotechnology programme focused on TB and HIV/AIDS.

A second strain of the Japanese encephalitis virus prevalent in East and South-East Asia is now being reported from India.

The stagnating funding for neglected disease research is raising concerns over the development of new diagnostics, vaccines and drugs.